Bionano Genomics IncBNGO
Price$1.57

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $30.2M-1.9% YoYTTM through 30 Jun 2026
Net Income -$32.2MTTM through 30 Jun 2026
Free Cash Flow -$20.5MTTM through 30 Jun 2026

Margins

Current
Gross Margin48.6%
EBITDA Margin-75.8%
Operating Margin-118.1%
Net Margin-106.6%

Returns

-22.2%ROE
-12.8%ROA

Balance Sheet Health

Debt / Equity0.27x
Current Ratio1.84x
Net Debt-$4.3Mnet cash position
Cash & Equivalents$3.7M

Quality Metrics

Altman Z-Score-22.05
Piotroski F-Score4 / 9
FCF Margin-67.9%
Rule of 40-61.4
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $28.5M
Diluted EPS-$3.01TTM
'21'22'23'24'25
FY2025: $-4.85

Dividend

No dividend

Capital Allocation

R&D Spend$12.2M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.